NextCure (NXTC) has filed a preliminary prospectus for an $86M IPO.
The Beltsville, MD-based biopharmaceutical firm develops immunotherapies for cancer and immune-related disorders that act by restoring immune function. Lead candidate is NC318, targeted to an immunomodulatory receptor called Siglec-15, currently being evaluated in a Phase 1/2 study in patients with advanced/metastatic solid tumors.
2018 Financials ($M): Operating Expenses: 23.2 (+49.7%); Net Loss: (22.8) (-47.1%); Cash Flow Ops: 8.0 (+164.0%).
